Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 1.00 |
| ▸ | RYR2 | Q92736 | 17/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192924 | 0.99 | KCNH2 (0.98) | KCNH2RYR2 | |
| Fumaric Acid SCHEMBL30481063 | 0.95 | KCNH2 (0.91) | KCNH2RYR2 | |
| SCHEMBL6867808 | 0.91 | RYR2 (0.86) | KCNH2RYR2 | |
| SCHEMBL13145783 | 0.91 | RYR2 (0.86) | KCNH2RYR2 | |
| SCHEMBL22803651 | 0.91 | KCNH2 (0.84) | KCNH2RYR2 | |
| SCHEMBL6866897 | 0.91 | RYR2 (1.00) | KCNH2RYR2 | |
| SCHEMBL8252834 | 0.89 | KCNH2 (0.79) | KCNH2RYR2 | |
| SCHEMBL2600723 | 0.89 | KCNH2 (0.79) | KCNH2RYR2 | |
| SCHEMBL13632685 | 0.88 | KCNH2 (0.78) | KCNH2RYR2 | |
| SCHEMBL8247295 | 0.87 | KCNH2 (0.76) | KCNH2RYR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844803-B2 | Renal dysfunction improving drug comprising optical isomer of 1,4-benzothiazepine-1-oxide derivative | AETAS PHARMA CO., LTD. (JP) | 2023-12-19 | — | — | US | disclosed |
| EP-3725315-B1 | RENAL DYSFUNCTION IMPROVING DRUG COMPRISING OPTICAL ISOMER OF 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE | AETAS PHARMA CO LTD (JP) | 2023-10-04 | — | — | EP | disclosed |
| US-20200390782-A1 | RENAL DYSFUNCTION IMPROVING DRUG COMPRISING OPTICAL ISOMER OF 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE | AETAS PHARMA CO., LTD. (JP) | 2020-12-17 | — | — | US | disclosed |
| EP-3725315-A1 | RENAL DYSFUNCTION IMPROVING DRUG COMPRISING OPTICAL ISOMER OF 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE | Aetas Pharma Co. Ltd. (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-9340533-B2 | 1,4-benzothiazepine-1-oxide derivative and pharmaceutical composition utilizing the same | Noboru, Kaneko (JP) | 2016-05-17 | — | — | US | disclosed |
| EP-2764867-A1 | Agents for preventing and treating disorders Involving modulation of the RYR receptors | The Trustees of Columbia University in the City of New York (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20140135313-A1 | 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION UTILIZING THE SAME | KANEKO, Noburo (JP) | 2014-05-15 | — | — | US | disclosed |
| US-8642586-B2 | 1,4-benzothiazepine-1-oxide derivative and pharmaceutical composition utilizing the same | Kaneko, Noboru (JP) | 2014-02-04 | — | — | US | disclosed |
| EP-2402333-B1 | 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION UTILIZING THE SAME | KANEKO NOBORU (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-1928850-B1 | AGENTS FOR PREVENTING AND TREATING DISORDERS INVOLVING MODULATION OF THE RYR RECEPTORS | UNIV COLUMBIA (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2006101497-A2 | NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006101496-A1 | NOVEL ANTI-ARRYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060194767-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2006-08-31 | — | — | US | disclosed |
| EP-1684735-A2 | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING EXERCISE-INDUCED CARDIAC ARRHYTHMIAS | The Trustees of Columbia University in the City of New York (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005094457-A2 | NOVEL ANTI-ARRHYTHMIC AND HEART FAILURE DRUGS THAT TARGET THE LEAK IN THE RYANODINE RECEPTOR (RYR2) AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050215540-A1 | Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2005-09-29 | — | — | US | disclosed |
| US-20050186640-A1 | Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RYR2) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-08-25 | — | — | US | disclosed |
| US-20050187386-A1 | Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2005-08-25 | — | — | US | disclosed |
| WO-2005037195-A2 | COMPOUNDS AND METHODS FOR TREATING AND PREVENTING EXERCISE-INDUCED CARDIAC ARRHYTHMIAS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) | 2005-04-28 | — | — | WO | disclosed |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11844803-B2 | Renal dysfunction improving drug comprising optical isomer of 1,4-benzothiazepine-1-oxide derivative | REN, CYP11B1, CYP11B2 | KCNH2 242/4885RYR2 316/4885 |
| US-20040229781-A1 | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias | RYR2, RYR1, FKBP4 | KCNH2 108/4885RYR2 1/4885 |
| US-20060194767-A1 | Novel agents for preventing and treating disorders involving modulation of the RyR receptors | RYR2, RYR1, ATP2A1 | KCNH2 315/4885RYR2 1/4885 |
| US-20050215540-A1 | Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof | RYR2, RYR1, ATP2A1 | KCNH2 79/4885RYR2 1/4885 |
| US-20140135313-A1 | 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION UTILIZING THE SAME | ADRA1D, HSD11B1, CACNA1D | KCNH2 151/4885RYR2 27/4885 |
| US-20200390782-A1 | RENAL DYSFUNCTION IMPROVING DRUG COMPRISING OPTICAL ISOMER OF 1,4-BENZOTHIAZEPINE-1-OXIDE DERIVATIVE | REN, CYP11B1, CYP11B2 | KCNH2 242/4885RYR2 316/4885 |
| US-20050187386-A1 | Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) | RYR2, RYR1, ATP2A3 | KCNH2 190/4885RYR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.